Jin-Hong Yoo

Jin-Hong Yoo

Auto-generated profile, based on publicly available information

Jin-Hong Yoo

Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
JYJin-Hong Yoo
Jin-Hong Yoo
Yoo JH. Infect Chemother. 2018 Jun;50(2):101-109. https://doi.org/10.3947/ic.2018.50.2.101

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JYJin-Hong Yoo
Jin-Hong Yoo
Yoo JH. J Korean Med Sci. 2019 Dec;35(4):e56. https://doi.org/10.3346/jkms.2020.35.e56

18 February 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
SCSung-Yeon Cho
Sung-Yeon Cho
DLDong-Gun Lee
Dong-Gun Lee
SCSu-Mi Choi
Su-Mi Choi
CPChulmin Park
Chulmin Park
HCHye-Sun Chun
Hye-Sun Chun
JYJin-Hong Yoo
Jin-Hong Yoo
Stenotrophomonas maltophilia causes serious infections in immunocompromised hosts. Here, we analyzed the clinical characteristics of S. maltophilia bloodstream infection (BSI) in patients with hematologic malignancies and evaluated in vitro synergistic effects of antimicrobial combinations. We retrospectively reviewed all consecutive episodes of S. maltophilia BSIs in adult hematologic patients from June 2009 to May 2014, with in vitro susceptibility and synergy tests using high-throughput bioluminescence assay performed for available clinical isolates. Among 11,004 admissions during 5-year period, 31 cases were identified as S. maltophilia BSIs. The incidence rate of S. maltophilia BSI was 0.134 cases/1,000 patient-days. Overall and attributable mortality of S. maltophilia BSI was 64.5% and 38.7%, respectively. Severe neutropenia (adjusted hazard ratio [HR] 5.24, p =0.013), shock at the onset of BSI (adjusted HR 6.05, p <0.001), and pneumonia (adjusted HR 3.15, p =0.017) were independent risk factors for mortality. In vitro susceptibilities to ceftazidime, levofloxacin, ticarcillin-clavulanic acid (TIM) and trimethoprim-sulfamethoxazole (SXT) were 11.1%, 44.0%, 40.7%, and 88.9%, respectively. MIC50/MIC90 for moxifloxacin and tigecycline were 1/4 mg/L and 4/8 mg/L. The 50% and 90% fractional inhibitory concentrations (FIC50/FIC90) of clinical isolates against a combination of SXT and TIM were 0.500/0.750. For SXT plus levofloxacin or moxifloxacin, FIC50/FIC90 were 0.625/1.000 and 0.625/0.625, respectively. S. maltophilia BSIs show high mortality, which is related to severe neutropenia, shock, and S. maltophilia pneumonia. Based upon drug susceptibility testing, the primary treatment of choice for S. maltophilia BSIs should be SXT in hematologic patients, rather than quinolones, with combination therapies including SXT serving as a feasible treatment option.

1 January 2025 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JYJin-Hong Yoo
Jin-Hong Yoo
Yoo JH. J Korean Med Sci. 2025 Jun;40(23):e187. https://doi.org/10.3346/jkms.2025.40.e187

2 August 2004 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
JYJ-H Yoo
J-H Yoo
DLD-G Lee
D-G Lee
SCS M Choi
S M Choi
JCJ-H Choi
J-H Choi
YPY-H Park
Y-H Park
CKC-C Kim
C-C Kim

29 October 2013 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
SCSung-Yeon Cho
Sung-Yeon Cho
DLDong-Gun Lee
Dong-Gun Lee
SCSu-Mi Choi
Su-Mi Choi
JKJae-Cheol Kwon
Jae-Cheol Kwon
SKSi-Hyun Kim
Si-Hyun Kim
JYJin-Hong Yoo
Jin-Hong Yoo
Background: Vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI) is generally associated with the delayed administration of adequate antibiotics. The identification of risk factors and outcomes of VRE BSI is necessary for establishing strategies for managing neutropenic fever in patients with hematological malignancies. Methods: We retrospectively analysed consecutive cases of enterococcal BSI in patients with neutropenia after chemotherapy or stem cell transplantation between July 2009 and December 2011 at a single center. Results: During the 30-month period, among 1,587 neutropenic patients, the incidence rate of enterococcal BSI was 1.76 cases per 1,000 person-days. Of the 91 enterococcal BSIs, there were 24 cases of VRE. VRE BSI was associated with E. faecium infection (P < .001), prolonged hospitalization (P = .025) and delayed administration (≥48 hours after the febrile episode) of adequate antibiotics (P = .002). The attributable mortality was 17% and 9% for VRE and vancomycin-susceptible Enterococcus (VSE), respectively (P = .447). The 30-day crude mortality was 27% and 23% for VRE and VSE, respectively (OR 1.38, 95% CI 0.53–3.59; P = .059). Only SAPS-II was an independent predictive factor for death (adjusted OR 1.12, 95% CI 1.08–1.17; P < .001). Conclusions: In conclusion, vancomycin resistance showed some trend towards increasing 30-day mortality, but is not statistically significant despite the delayed use of adequate antibiotics (≥48 hours). Only underlying severity of medical condition predicts poor outcome in a relatively homogeneous group of neutropenic patients.